PATENT CLAIM ANALYSIS

Application Number: 15860298
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "248100"]

Abstract:
Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to,  Mycobacterium avium  subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.

Claim (Index 4):
The pharmaceutical composition of  claim 1  wherein the fixed-dose composition is a tablet.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 86.0
- Lexical Diversity: 2.69231
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15585879', '14271814', '12918310', '13722395', '14271758']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7500991038370797
- 35 USC 102 Novelty (BERT): 0.5554182116109767
- Combined Prediction Score: 0.7306310146144693
- Mean Citation Score: 355.9997
- Max Citation Score: 420.46298
- Similarity Product: 300.3101065691662

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test